Form 4: Cue Biopharma's Chief Medical Officer Acquires Stock Options

Matteo Levisetti, Chief Medical Officer of Cue Biopharma, acquires stock options exercisable for 250,000 shares of common stock.

Summary

• On March 21, 2025, Matteo Levisetti, the Chief Medical Officer of Cue Biopharma, Inc., acquired stock options for 250,000 shares.
• The exercise price of the stock options is $0.99 per share.
• The options become exercisable in eight equal semi-annual installments starting September 21, 2025.
• The expiration date for these options is March 20, 2035.
• Following the transaction, Levisetti directly owns derivative securities for 250,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and suggests confidence in the executive's ability to contribute to the company's success. However, it's a routine event and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech industry. Stock options align the executive's interests with those of the shareholders.

Comparison to Industry Standards

• Granting stock options to key executives is a common practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options as part of their compensation packages to attract and retain talent.
• The vesting schedule and exercise price are generally determined based on industry benchmarks and the executive's role and performance.

Stakeholder Impact

• The granting of stock options could potentially align the interests of the Chief Medical Officer with those of the shareholders, encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, Form 4, insider trading, Cue Biopharma, Matteo Levisetti, Chief Medical Officer, equity, CUE